Kazancioglu Alp, Ocak Melike, Sahiner Umit Murat, Soyer Ozge, Sekerel Bulent Enis
Department of Pediatric Allergy, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Pediatr Allergy Immunol. 2025 Jan;36(1):e70022. doi: 10.1111/pai.70022.
Sesame allergy (SA) is a growing concern because of its association with severe reactions and the limited knowledge of long-term outcomes.
This retrospective study aimed to identify the risk factors influencing persistent SA (PSA) in children to improve management and select suitable candidates for oral immunotherapy (OIT).
We analyzed the electronic medical records of 84 children with confirmed SA, as defined by consistent clinical reactions and immunoglobulin E (IgE)-mediated sensitization. Patients were followed for a median (IQR) of 56.5 (46.0-82.5) months.
Most participants were male (72.6%) with concurrent food allergies (71.4%). They experienced a median (IQR) of 3.0 (2.0-3.7) allergic episodes, with 46.4% experiencing at least one anaphylactic reaction. PSA was observed in 82.1% (69/84) of the patients. A larger skin prick test (SPT) wheal size at the first reaction (adjusted OR = 1.79, CI:1.05-3.04; p = .03) and allergic reaction grade≥2 (adjusted OR = 19.93, CI:1.37-289.13; p = .02) were independent risk factors for persistence. A 3-fold increase in the likelihood of persistence was observed in patients with SPT results greater than 6.7 mm at first reaction compared with those with results less than 6.7 mm during follow-up (HR = 3.08; CI:1.17-8.12; p = .02). Patients with sustained or increased SPT wheal size (93% remained allergic) and specific IgE (95% remained allergic) at the final visit were more likely to have PSA, whereas those with decreased levels (37% and 39% developed natural tolerance, respectively) were less likely to have resolved SA.
This study identified novel risk factors for PSA, including SPT wheal size at the first reaction, reaction severity, and sustained sensitization markers. These findings can inform management strategies and the selection of OIT candidates. Further long-term studies are crucial to elucidate the natural history of SA across populations and to evaluate early interventions, such as OIT.
芝麻过敏(SA)因其与严重反应相关且对长期预后了解有限,日益受到关注。
这项回顾性研究旨在确定影响儿童持续性芝麻过敏(PSA)的危险因素,以改善管理并为口服免疫疗法(OIT)选择合适的候选者。
我们分析了84例确诊为SA的儿童的电子病历,SA的定义为有一致的临床反应和免疫球蛋白E(IgE)介导的致敏。对患者进行了中位(四分位间距)56.5(46.0 - 82.5)个月的随访。
大多数参与者为男性(72.6%),并伴有食物过敏(71.4%)。他们经历了中位(四分位间距)3.0(2.0 - 3.7)次过敏发作,46.4%的人经历过至少一次过敏反应。82.1%(69/84)的患者观察到PSA。首次反应时较大的皮肤点刺试验(SPT)风团大小(调整后OR = 1.79,CI:1.05 - 3.04;p = 0.03)和过敏反应分级≥2(调整后OR = 19.93,CI:1.37 - 289.13;p = 0.02)是持续性的独立危险因素。与随访期间结果小于6.7mm的患者相比,首次反应时SPT结果大于6.7mm的患者持续性可能性增加3倍(HR = 3.08;CI:1.17 - 8.12;p = 0.02)。最后一次就诊时SPT风团大小持续或增加(93%仍过敏)以及特异性IgE(95%仍过敏)的患者更有可能患有PSA,而水平降低的患者(分别有37%和39%产生自然耐受)SA缓解的可能性较小。
本研究确定了PSA的新危险因素,包括首次反应时的SPT风团大小、反应严重程度和持续致敏标志物。这些发现可为管理策略和OIT候选者的选择提供参考。进一步的长期研究对于阐明不同人群中SA的自然病程以及评估早期干预措施(如OIT)至关重要。